Clinical trials sponsored by ETOP IBCSG Partners Foundation
5
Recruiting trials
6
Conditions studied
Phase breakdown
Phase 2 2Phase 3 3
Conditions studied
| Condition | Trials |
|---|---|
| Lung cancer | 5 |
| Non Small Cell Lung Cancer | 3 |
| Extensive Stage Lung Small Cell Cancer | 1 |
| Melanoma | 1 |
| SCLC,Extensive Stage | 1 |
| SLFN11-positive | 1 |
Recruiting trials led by ETOP IBCSG Partners Foundation
- A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
- A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
- A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
- Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
- Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
Common questions
How many trials is ETOP IBCSG Partners Foundation recruiting for?
ETOP IBCSG Partners Foundation is the lead sponsor of 5 recruiting trials.
Is this list complete?
No. For the full record, search ClinicalTrials.gov.